Novavax (NVAX) smashed its Q1 2025 earnings today. The stock rocketed 33% in pre-market trading after the company reported a stunning $518 million profit for Q1 2025. This marks a complete turnaround for the biotech company, which has struggled in the past but is now riding high thanks to explosive vaccine sales and a smart financial strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novavax’s Q1 Results Blow Expectations Out of the Water
Novavax shocked analysts with $667 million in revenue for Q1 2025—way above the $94 million it posted last year. The star player in this performance? Nuvaxovid, Novavax’s COVID-19 vaccine, which racked up $608 million in product sales. With this major revenue boost, the company is finally seeing the fruits of its hard work.
CEO John C. Jacobs was quick to highlight that the company is not just celebrating today but building long-term value for shareholders. “We’ve delivered strong results and are focused on maintaining this momentum,” he said.
Novavax Seals $518M Net Income and $3.22 EPS Turnaround
The big win? Novavax posted $518 million in net income. It turned last year’s $147 million loss into a major profit. The company’s EPS came in at $3.22, crushing analyst expectations. This kind of turnaround doesn’t happen every day, especially in biotech.
NVAX Executes Share Buybacks and Drives Financial Strategy Forward
The company isn’t stopping at earnings. Novavax announced share buybacks. This signals confidence in its future. With a healthy $263 million in cash reserves, it’s clear that the company is focused on expanding its pipeline while rewarding shareholders.
Novavax Looks Ahead with Optimism
Novavax raised its 2025 revenue guidance to $975 million–$1.025 billion, driven by expected continued sales of Nuvaxovid. With a $175 million milestone payment from Sanofi also on the horizon, the company is poised for even greater success.
Is NVAX Stock a Buy, Hold, or Sell?
Currently, Novavax holds a Moderate Buy rating, with two analysts recommending it as a Buy and two others taking a Hold stance. The average 12-month price target for Novavax is set at $14.25, with a high forecast of $19.00 and a low of $9.00. This translates into an impressive 139.5% upside from its current price of $5.95, which suggests that analysts see substantial growth potential moving forward. Given the company’s recent strong performance, analysts may revise their targets upward in the near future.
